US.CRL · Charles River Laboratories

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.3,
      "details": {
        "atrPct": 3.8246357615894038,
        "turnoverUsdM": 284.281962,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.CRL",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 278.8992,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 2,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 7.6,
      "take_profit_price": 328.3349,
      "target_multiplier": 1.9,
      "technical_strength": 1.8,
      "take_profit_percent": 8.7
    },
    "positionPoints": 1.3,
    "stopLossPoints": 1.2,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 7.6492715231788075,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 60.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 53.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 293.487,
    "ma50": 287.2762,
    "close": 302,
    "prevClose": 299.02,
    "avgVolume20": 1029617,
    "volumeRatio": 0.91,
    "changePercent": 1
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.005661039149551739,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 0.9110036872514009,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 1.2066209999920354,
      "volat_points": 2,
      "day_range_pct": 0.046937052980132385,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 60.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 1.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 30,
        "contribution": 1.5
      },
      {
        "raw": 11.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 58,
        "contribution": 11.6
      },
      {
        "raw": 11.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 74.67,
        "contribution": 11.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 5.9,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 59,
        "contribution": 5.9
      },
      {
        "raw": 17.7,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 59,
        "contribution": 17.7
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 53.9,
    "details": [
      "基本面分析總分: 1.5/5分",
      "資金流分析總分: 11.6/20分",
      "市場環境分析總分: 11.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 5.9/10分",
      "技術信號分析總分: 17.7/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 1.5,
      "資金流": 11.6,
      "市場環境": 11.2,
      "情緒分析": 4,
      "技術信號": 17.7,
      "風險管理": 5.9
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 284.281962,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 3.2,
          "obvPoints": 0.8,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.CRL",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "良好",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.27
            }
          },
          "trend": {
            "score": 2.8,
            "details": {
              "qqq": {
                "ma20": 742.5420041499999,
                "ma50": 726.6542014600002,
                "name": "QQQ",
                "close": 728.84003,
                "points": 1.4
              },
              "spy": {
                "ma20": 770.64649665,
                "ma50": 768.5679965799999,
                "name": "SPY",
                "close": 769.59998,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.8246357615894038,
          "atrPoints": 2,
          "cciPoints": 4,
          "vixPoints": 2.4,
          "marketTrendPoints": 2.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142697487,
                "url": "https://finnhub.io/api/news?id=37c828691300a9de678d26bd8593aede8f0b62d682cd1ebd6b5c9150950f1f69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "PGNY vs. CRL: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1791384004,
                "headline": "PGNY or CRL: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 142592897,
                "url": "https://finnhub.io/api/news?id=73d6aea502d0d31bd3b4f84722916a1926fcbb56cee537a66e1d38055c72cb31",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Price targets for Charles River Laboratories International have shifted higher in recent research, with several firms now pointing to a range between US$219 and US$340, alongside a new fair value estimate of US$305. That cluster of higher targets aligns with more constructive analyst commentary after the company’s investor and analyst days, as firms factor in the updated long range plan and revised margin goals. As you read on, you will see how to track these changes and what to watch as the...",
                "category": "company",
                "datetime": 1790967988,
                "headline": "Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases"
              },
              {
                "id": 142499581,
                "url": "https://finnhub.io/api/news?id=7f51eba51258fdf6cd630123ee9af8f152c141f938e9c8148006d4aee3dc5cd2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Cooke & Bieler, an investment management firm, released its second-quarter investor letter for “Mid Cap Value Equity Strategy.” The letter can be downloaded here. U.S. equities rallied significantly in Q2, driven by shifting geopolitical risks and strong investor appetite for high-beta stocks, particularly in the tech sector, contributing to the S&P 500® and Nasdaq’s best […]",
                "category": "company",
                "datetime": 1790698275,
                "headline": "Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery"
              },
              {
                "id": 142402006,
                "url": "https://finnhub.io/api/news?id=42da75f3364248802af2056a822959beeb514891c450db0e2602056cc50c92c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International has seen its share price move sharply over the past year, and that kind of run naturally raises a question for you as an investor. Are the cash flows that the business can generate enough to support where the stock now trades? The stock has returned 102.3% over the past 12 months, which puts real pressure on the case that its current valuation can still be explained by its underlying cash generation. Recent moves to expand outsourced services in areas...",
                "category": "company",
                "datetime": 1790316582,
                "headline": "Charles River Laboratories (CRL) Stock Still Seems Reasonable Despite Rapid Cell Banking Launch"
              },
              {
                "id": 142387947,
                "url": "https://finnhub.io/api/news?id=47b738c3783bc88c4221394848f31db0a9c7fff9a26d3d04bcfb555d444675b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 5.7% in the afternoon session after the company outlined long-term financial targets through 2030 and raised its 2026 earnings outlook at its Investor Day.",
                "category": "company",
                "datetime": 1790291098,
                "headline": "Why Charles River Laboratories (CRL) Stock Is Up Today"
              },
              {
                "id": 142385395,
                "url": "https://finnhub.io/api/news?id=6f5b2fba693b22fa73e8e6a1e1077de6b506ff84c3e4f65e588abdc05bf56df2",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day September 24, 2026 9:00 AM EDTCompany ParticipantsTodd Spencer - Corporate Vice...",
                "category": "company",
                "datetime": 1790263799,
                "headline": "Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript"
              },
              {
                "id": 142379184,
                "url": "https://finnhub.io/api/news?id=c9c3fd21de2cd9847355174c946ed9a05e8fef2bcfe94440baa4e75ebe390b60",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "2026-09-24. The following slide deck was published by Charles River Laboratories International, Inc.",
                "category": "company",
                "datetime": 1790242663,
                "headline": "Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day - Slideshow"
              },
              {
                "id": 142319439,
                "url": "https://finnhub.io/api/news?id=e74103a9743a075eb466d899fb135f9e669f504b3b882d1ade6c13cb524db239",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "On August 20, Charles River Laboratories (NYSE:CRL) announced a collaboration with Medigen Vaccine Biologics Corp/MVC to apply next-generation sequencing to MVC’s new multivalent enterovirus vaccine program. On its own, the deal is small. But it shows Charles River finding fresh uses for the sequencing technology it picked up through an earlier acquisition, and it lands […]",
                "category": "company",
                "datetime": 1790044484,
                "headline": "Charles River’s (CRL) Vaccine Push Meets A Bumpy Quarter"
              }
            ],
            "raw_source": [
              {
                "id": 142881848,
                "url": "https://finnhub.io/api/news?id=d92b840d57c7cf26fe9122c59c96eb5effa81ac8761ad4ac4bb9f698ce01fff4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "The partnership focuses on biologics quality control as well as viral and release testing under cGMP standards.",
                "category": "company",
                "datetime": 1791973542,
                "headline": "Charles River partners with Magellan Stem Cells on cell therapy"
              },
              {
                "id": 142872378,
                "url": "https://finnhub.io/api/news?id=62738761f42c073d33babe49d64f521c4f661034a6934bafccd6cd78abbca7c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Outsource clinical trials and leverage AI, decentralized models and regulatory expertise to cut costs, accelerate drug development and expand patient access.Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- \"Healthcare Contract Research Organization (CRO) - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. Global Healthcare Contract Research Organization (CRO) Market to Reach US$63.3 Billion by 2032 The global Healthcare Contract Research Organization (CRO) market, e",
                "category": "company",
                "datetime": 1791965460,
                "headline": "Healthcare Contract Research Organization (CRO) - Global Strategic Business Report: Secure Share of US$63.3 Billion Market by 2032 as IQVIA, ICON, Charles River, and Syneos Health Accelerate AI Trials"
              },
              {
                "id": 142882861,
                "url": "https://finnhub.io/api/news?id=93c15420dba820f73acdaf92c76e738f90d3f27ffc0b3533e13299a950b32e2a",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Morgan Stanley  analyst Ricky Goldwasser   maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $340.",
                "category": "company",
                "datetime": 1791894279,
                "headline": "Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340"
              },
              {
                "id": 142847677,
                "url": "https://finnhub.io/api/news?id=cddde621353a46d82cf197be60342f9be17dd2d28c88a4b6ef3b00fae32ed5d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., October 13, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River’s specialized expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and r",
                "category": "company",
                "datetime": 1791892800,
                "headline": "Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development"
              },
              {
                "id": 142849184,
                "url": "https://finnhub.io/api/news?id=cae78aa67d83366e974f3475b844be12c4846a61277b95a025a3a90fd39e09b6",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical",
                "category": "company",
                "datetime": 1791878667,
                "headline": "Charles River Laboratories International Partners With Magellan Stem Cells For Development, Clinical Advancement Of Stem Cell-Based Therapies, Regenerative Medicine Solutions"
              },
              {
                "id": 142821923,
                "url": "https://finnhub.io/api/news?id=53efda3451be265502610e54f2aac7d0c18c98fe0810a2e8a51f996620eccbf2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
                "category": "company",
                "datetime": 1791816423,
                "headline": "1 S&P 500 Stock to Target This Week and 2 We Question"
              },
              {
                "id": 142820380,
                "url": "https://finnhub.io/api/news?id=423149643bbad89b0db5f5911a4cddf6c995655e87d48181f8346bb1364ce1df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Boost ROI with AI-led design, automated high-throughput screening, customizable libraries, local production and diversified sourcing to cut costs and speed development.Dublin, Oct. 12, 2026 (GLOBE NEWSWIRE) -- \"Synthetic Antibody Library Global Market Report 2026\" has been added to ResearchAndMarkets.com's offering. The global synthetic antibody library market is experiencing rapid expansion, supported by rising demand for therapeutic antibodies, continued growth in biopharmaceutical research an",
                "category": "company",
                "datetime": 1791813600,
                "headline": "Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera"
              },
              {
                "id": 142760739,
                "url": "https://finnhub.io/api/news?id=9c7afb02e7e9d7abcc03d3cb0a983871d3e7356993eb8a452fb378da3b71b958",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., October 09, 2026--Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call",
                "category": "company",
                "datetime": 1791547200,
                "headline": "Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call"
              },
              {
                "id": 142730419,
                "url": "https://finnhub.io/api/news?id=5741fde32d2d428cfb091510e2b9dc970e9a9cdc9798a0a9de13df26fb600389",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1791477301,
                "headline": "Stay informed with the top movers within the S&P500 index on Thursday."
              },
              {
                "id": 142697487,
                "url": "https://finnhub.io/api/news?id=37c828691300a9de678d26bd8593aede8f0b62d682cd1ebd6b5c9150950f1f69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "PGNY vs. CRL: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1791384004,
                "headline": "PGNY or CRL: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 142695289,
                "url": "https://finnhub.io/api/news?id=6a5ab641dfa540f4273e0bc7343b63546d8bed6db48b9a05cc96fc59a2885f95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "CRL shares have surged 75.8% in a year as RMS trends improve, AI-enabled testing expands and cash flow supports buybacks and investment.",
                "category": "company",
                "datetime": 1791377460,
                "headline": "Charles River Gains 75.8% in a Year: What's Driving the Rally?"
              },
              {
                "id": 142665917,
                "url": "https://finnhub.io/api/news?id=96f2244ba53353df9f32cdb272b02c1bd237949d5c8d05b5b004c1bb61985f59",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "TFX's Vascular growth, Asia expansion and improved leverage support the outlook, but tariffs, input costs and margin pressure remain key risks.",
                "category": "company",
                "datetime": 1791296940,
                "headline": "Is It Prudent to Add Teleflex Stock to Your Portfolio Now?"
              },
              {
                "id": 142663488,
                "url": "https://finnhub.io/api/news?id=442468620f7300edd97e96030827e9ed4020cc52e307d09ca48212ba3f770b1d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass. & LONDON, October 06, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new capability within Charles River's Apollo® platform that connects and digitizes laboratory execution, built on Autolomous's autoloMATE® digital Laboratory Execution System (LES). The launch demonstrates continued progress on Charles River's strategic commitment to modernize and digitize laboratory workflows. Apollo® Orches",
                "category": "company",
                "datetime": 1791288000,
                "headline": "Charles River and Autolomous Partner to Transform Laboratory Execution Systems"
              },
              {
                "id": 142664252,
                "url": "https://finnhub.io/api/news?id=848f97ea160777aeb7ed35e35b75b28220a8868d46bf0b3145004ec3da03062c",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Partnership reinforces continued investment in digitization, automation, and client-facing transparencyCharles River Laboratories International, Inc. (NYSE:CRL) and Autolomous today announced the launch of Apollo",
                "category": "company",
                "datetime": 1791274390,
                "headline": "Charles River Laboratories and Autolomous Launch Apollo Orchestrate To Digitize Laboratory Execution Through autoloMATE Integration"
              },
              {
                "id": 142638288,
                "url": "https://finnhub.io/api/news?id=4796f000e83db0803c6b2ad30c002a2fc93fd2d01cc72622994706b14f78ea94",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.",
                "category": "company",
                "datetime": 1791227101,
                "headline": "Uncover the latest developments among S&P500 stocks in today's session."
              },
              {
                "id": 142637485,
                "url": "https://finnhub.io/api/news?id=67961b010b1f3caecc8f221b133dc532a01b4d12e570aa9d8e37f37167ccb5a0",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.",
                "category": "company",
                "datetime": 1791218101,
                "headline": "Which S&P500 stocks are moving on Monday?"
              },
              {
                "id": 142592897,
                "url": "https://finnhub.io/api/news?id=73d6aea502d0d31bd3b4f84722916a1926fcbb56cee537a66e1d38055c72cb31",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Price targets for Charles River Laboratories International have shifted higher in recent research, with several firms now pointing to a range between US$219 and US$340, alongside a new fair value estimate of US$305. That cluster of higher targets aligns with more constructive analyst commentary after the company’s investor and analyst days, as firms factor in the updated long range plan and revised margin goals. As you read on, you will see how to track these changes and what to watch as the...",
                "category": "company",
                "datetime": 1790967988,
                "headline": "Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases"
              },
              {
                "id": 142577515,
                "url": "https://finnhub.io/api/news?id=4004dabfc4e71581127dd887539a0ecf3abbbdbfca0c74f5d1873ab9ad91f51b",
                "image": "",
                "source": "Fintel",
                "related": "CRL",
                "summary": "",
                "category": "company",
                "datetime": 1790925229,
                "headline": "Charles River Laboratories International Consensus Price Target Increased by 11.46% to $307.39"
              },
              {
                "id": 142518422,
                "url": "https://finnhub.io/api/news?id=4f000e219b76905d0e4602a2357c480f40a8a0d43c3dffe4cc108d40fa5b5d11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Animal model demand is rising with drug and vaccine research. CRISPR, AI and humanized models offer opportunities, while ethical scrutiny spurs humane alternatives.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- \"Animal Model - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global animal model market was estimated at US$2.1 billion in 2025 and is projected to reach US$3.6 billion by 2032, advancing at a compound annual growth rate (CAGR) of 7.9%. Market exp",
                "category": "company",
                "datetime": 1790774880,
                "headline": "Animal Model - Global Strategic Business Report:  Market Size to Surge to $3.6 Billion by 2032 as CRISPR Disrupts R&D - Benchmark Charles River, Biocytogen, Crown Bioscience, Cyagen and The Jackson Laboratory"
              },
              {
                "id": 142517531,
                "url": "https://finnhub.io/api/news?id=4bd4d48cb235fd301171991d0bfe3cb1a9387d7e335c5a84377e0aab6d16e21c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Here is how Aveanna Healthcare (AVAH) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1790772002,
                "headline": "Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?"
              },
              {
                "id": 142520420,
                "url": "https://finnhub.io/api/news?id=3bcdfc31b28a1e9d32bf937b1007a9d54474bac7dbab9269b99cd19feddf03cc",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 3.32% on an annualized basis producing an average annual return of 16.72%. Currently, Charles River has a market capitalization of $15.15",
                "category": "company",
                "datetime": 1790766039,
                "headline": "Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today"
              },
              {
                "id": 142520421,
                "url": "https://finnhub.io/api/news?id=cc0cb7255ec4f1bd0a5564f8462ab5a34a8f861a00590f3143b8ce54803c43bd",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "UBS  analyst Kevin Caliendo   reinstates Charles River (NYSE:CRL) with a Buy and announces $357 price target.",
                "category": "company",
                "datetime": 1790757739,
                "headline": "UBS Reinstates Buy on Charles River, Announces $357 Price Target"
              },
              {
                "id": 142499581,
                "url": "https://finnhub.io/api/news?id=7f51eba51258fdf6cd630123ee9af8f152c141f938e9c8148006d4aee3dc5cd2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Cooke & Bieler, an investment management firm, released its second-quarter investor letter for “Mid Cap Value Equity Strategy.” The letter can be downloaded here. U.S. equities rallied significantly in Q2, driven by shifting geopolitical risks and strong investor appetite for high-beta stocks, particularly in the tech sector, contributing to the S&P 500® and Nasdaq’s best […]",
                "category": "company",
                "datetime": 1790698275,
                "headline": "Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery"
              },
              {
                "id": 142498448,
                "url": "https://finnhub.io/api/news?id=33d389ce10e1c3a470a93edeb6350bbdab2e11354e2d65d66fcec4c7016e4514",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Stricter quality rules, complex biologics and outsourcing are driving demand for impurity isolation, synthesis and analytics, creating opportunities for specialized labs and CROs.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- \"Pharmaceutical Impurity Synthesis and Isolation Services - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global pharmaceutical impurity synthesis and isolation services market was valued at US$1.3 billion in 2024 and is projected to",
                "category": "company",
                "datetime": 1790697120,
                "headline": "Pharmaceutical Impurity Synthesis and Isolation Services  Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River"
              },
              {
                "id": 142498449,
                "url": "https://finnhub.io/api/news?id=b4e488f22dcd680cd9d6f1073f1177520302265edfe111909503cd1374c8c6fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "AI, machine learning, cloud analytics and multi-omics are accelerating drug discovery, enabling targeted, personalized therapies while reducing development time, cost and risk.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- \"Computer-Aided Drug Discovery - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global computer-aided drug discovery market was estimated at US$3.2 billion in 2025 and is projected to reach US$6.7 billion by 2032, expanding at a compound",
                "category": "company",
                "datetime": 1790697060,
                "headline": "Computer-Aided Drug Discovery - Global Strategic Business Report: Capitalize on 11% CAGR as AI-led CADD surges from $3.2B in 2025 to $6.7B by 2032—benchmark Bayer, Charles River Laboratories, Pharmaron and Chemical Computing Group to secure growth."
              },
              {
                "id": 142495085,
                "url": "https://finnhub.io/api/news?id=1f13747f30781afd5effdb4cfed035abc4e598b4fd9cf0d20bc8009c926b865a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development frameworkBuilds on NorthStrive Biosciences’ expanding manufacturing and characterization capabilities behind its engineered probiotic platform targeting muscle preservation, including for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq:",
                "category": "company",
                "datetime": 1790681580,
                "headline": "NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs"
              },
              {
                "id": 142487027,
                "url": "https://finnhub.io/api/news?id=23e5453460dd9e1f12da1cd9842974b512e65d80948df3cb7bb3f7e48175af39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Boost ROI by matching models to research goals, standardizing studies, investing in quality data and training, integrating validated AI and alternatives, and aligning global partnershipsDublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- \"Experimental Animal Model Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering. This market research report examines the global Experimental Animal Model Market, which is projected to reach USD 1.31 billion in 2026 and expand at a comp",
                "category": "company",
                "datetime": 1790669220,
                "headline": "Global Experimental Animal Model Market Outlook and Forecast, 2026-2032 - AI-Enabled Research and Advanced Transgenic and Oncology Models Drive 9.18% CAGR Toward US$2.23 Billion, With Charles River, The Jackson Laboratory, Taconic Biosciences and Crown Bioscience Profiled"
              },
              {
                "id": 142467316,
                "url": "https://finnhub.io/api/news?id=da8b2e74678b76f253471de9bda93f56ad89236250cb85d9012c72196928a9af",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Jefferies  analyst David Windley   maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $305 to $340.",
                "category": "company",
                "datetime": 1790589930,
                "headline": "Jefferies Maintains Buy on Charles River, Raises Price Target to $340"
              },
              {
                "id": 142452869,
                "url": "https://finnhub.io/api/news?id=da87991122131ba1bc51d2b82e98e0e933eff651c52951f9b03cee7151f06fa8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories has outperformed the broader market over the past year, while analysts remain bullish on the company’s outlook.",
                "category": "company",
                "datetime": 1790542514,
                "headline": "Is Charles River Laboratories Stock Outperforming the S&P 500?"
              },
              {
                "id": 142431565,
                "url": "https://finnhub.io/api/news?id=bd97aef9c07a85a3b0403cde91733089cf1f386aa4a2a8a4ea3fdfb148209cae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (NYSE:CRL) outlined a strategy to accelerate growth, expand margins and modernize its operations during its 2026 Investor Day, setting financial targets through 2030 that include 5% to 7% organic revenue growth, an approximately 24% non-GAAP operating margin",
                "category": "company",
                "datetime": 1790384521,
                "headline": "Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan"
              },
              {
                "id": 142438323,
                "url": "https://finnhub.io/api/news?id=f64902b156e51968f8472d757adea49fd6dfd43ab176c85ace2d79c66f2e31e8",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Deutsche Bank  analyst Justin Bowers   maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $320.",
                "category": "company",
                "datetime": 1790339347,
                "headline": "Deutsche Bank Maintains Buy on Charles River, Raises Price Target to $320"
              },
              {
                "id": 142422937,
                "url": "https://finnhub.io/api/news?id=503eae205e8311b47407630a099d37c1ebc08fcac9e74631bad61f49ef982ae9",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "TD Cowen  analyst Charles Rhyee   maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $325.",
                "category": "company",
                "datetime": 1790331879,
                "headline": "TD Cowen Maintains Buy on Charles River, Raises Price Target to $325"
              },
              {
                "id": 142422938,
                "url": "https://finnhub.io/api/news?id=ea9efbffadd3510acdca4b68cee9fface3c802eb69248200128cada685ec337e",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Evercore ISI Group  analyst Ross Muken   maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $320 to $330.",
                "category": "company",
                "datetime": 1790331719,
                "headline": "Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $330"
              },
              {
                "id": 142422939,
                "url": "https://finnhub.io/api/news?id=c09b9bf609cd928c8d605fc1713b96f1cbf5334546fe74fd61fb7948c451b729",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "RBC Capital  analyst Ryan Halsted   maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $282 to $322.",
                "category": "company",
                "datetime": 1790329577,
                "headline": "RBC Capital Maintains Outperform on Charles River, Raises Price Target to $322"
              },
              {
                "id": 142422940,
                "url": "https://finnhub.io/api/news?id=93852949fe84b507c7dc838d6428a4e13e88285fa5fcf70009fcd7596169ffbe",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Barclays  analyst Luke Sergott   maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $330.",
                "category": "company",
                "datetime": 1790325141,
                "headline": "Barclays Maintains Overweight on Charles River, Raises Price Target to $330"
              },
              {
                "id": 142421440,
                "url": "https://finnhub.io/api/news?id=811cfc98c0f6098a703ed0ec518579d54e0410b864d8327c06e5f99fa9989ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254790315/image_2254790315.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Charles River Laboratories has doubled over the past year, outperforming despite regulatory and AI-related concerns. Click for this CRL stock update.",
                "category": "company",
                "datetime": 1790325014,
                "headline": "Charles River Laboratories: Positive Investor Day Is Fully Priced In"
              },
              {
                "id": 142422941,
                "url": "https://finnhub.io/api/news?id=e5066d348aed8e386edd6c90545afbca1b3488663b992a52f45b3b7b00cf631c",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Mizuho  analyst Ann Hynes   maintains Charles River (NYSE:CRL) with a Neutral and raises the price target from $264 to $295.",
                "category": "company",
                "datetime": 1790324119,
                "headline": "Mizuho Maintains Neutral on Charles River, Raises Price Target to $295"
              },
              {
                "id": 142422942,
                "url": "https://finnhub.io/api/news?id=9aede5f63a07646a47697cda4d6a9cc33dc8ca4ba5ec8eb1354c5334373c654a",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Baird  analyst Eric Coldwell   maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $291 to $334.",
                "category": "company",
                "datetime": 1790321165,
                "headline": "Baird Maintains Outperform on Charles River, Raises Price Target to $334"
              },
              {
                "id": 142414133,
                "url": "https://finnhub.io/api/news?id=f4295499197bd6a9de8d58c9c7c1374eb6f03327aba6b2783a0480cc9096195d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.",
                "category": "company",
                "datetime": 1790320680,
                "headline": "CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?"
              },
              {
                "id": 142402006,
                "url": "https://finnhub.io/api/news?id=42da75f3364248802af2056a822959beeb514891c450db0e2602056cc50c92c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International has seen its share price move sharply over the past year, and that kind of run naturally raises a question for you as an investor. Are the cash flows that the business can generate enough to support where the stock now trades? The stock has returned 102.3% over the past 12 months, which puts real pressure on the case that its current valuation can still be explained by its underlying cash generation. Recent moves to expand outsourced services in areas...",
                "category": "company",
                "datetime": 1790316582,
                "headline": "Charles River Laboratories (CRL) Stock Still Seems Reasonable Despite Rapid Cell Banking Launch"
              },
              {
                "id": 142387947,
                "url": "https://finnhub.io/api/news?id=47b738c3783bc88c4221394848f31db0a9c7fff9a26d3d04bcfb555d444675b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 5.7% in the afternoon session after the company outlined long-term financial targets through 2030 and raised its 2026 earnings outlook at its Investor Day.",
                "category": "company",
                "datetime": 1790291098,
                "headline": "Why Charles River Laboratories (CRL) Stock Is Up Today"
              },
              {
                "id": 142385317,
                "url": "https://finnhub.io/api/news?id=f6f2a26b9f5647288b5da04eda91284fe1679478b8b585e97013ed1ba637efe8",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1790276701,
                "headline": "Discover which S&P500 stocks are making waves on Thursday."
              },
              {
                "id": 142384123,
                "url": "https://finnhub.io/api/news?id=dc1a57203f768e8c465d0c09732c290a21cef549361c1549da309d17b77fc56a",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1790267701,
                "headline": "Explore the top gainers and losers within the S&P500 index in today's session."
              },
              {
                "id": 142385395,
                "url": "https://finnhub.io/api/news?id=6f5b2fba693b22fa73e8e6a1e1077de6b506ff84c3e4f65e588abdc05bf56df2",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day September 24, 2026 9:00 AM EDTCompany ParticipantsTodd Spencer - Corporate Vice...",
                "category": "company",
                "datetime": 1790263799,
                "headline": "Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript"
              },
              {
                "id": 142421668,
                "url": "https://finnhub.io/api/news?id=f659ca086a8fcedf0d0610b9b82a2c2c88705caf1d6794a316ed7f512bf7db64",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/24/Strait-Of-Hormuz-Disruptions-Add-Pressur.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Stocks pared a sharp morning selloff after sources said US and Iranian negotiators are discussing a phased deal to reopen the Strait of Hormuz.",
                "category": "company",
                "datetime": 1790256721,
                "headline": "S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today"
              },
              {
                "id": 142378283,
                "url": "https://finnhub.io/api/news?id=a8a984fffb4c90fac1ae5ea567d08372f13a17d94b853b64ecc24f97b900c9a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Opportunities center on AI-enabled decentralized trials, therapeutic specialization, global patient recruitment, regulatory support, real-world evidence and integrated partnerships.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- \"Contract Research Organization Services Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering. The Contract Research Organization Services Market research report provides strategic analysis of a sector projected to reach USD 87.43 billion in",
                "category": "company",
                "datetime": 1790254860,
                "headline": "Contract Research Organization Services Market Forecasts Growth from $107.03B (2025) to $180.56B by 2030, Profiling IQVIA, Charles River, Syneos Health & WuXi AppTec"
              },
              {
                "id": 142380438,
                "url": "https://finnhub.io/api/news?id=a2ef362ffb079b4895e7b59dc86e83f637663f2a436f38c8296c0f31d591c263",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Opportunities include validated AI, cloud safety platforms, real-world evidence, integrated pharmacovigilance, patient-centric reporting and expansion in emerging markets.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- \"Drug Safety Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering. The global Drug Safety Market research report examines growth trends, regulatory developments, technology adoption, and regional pharmacovigilance priorities. The market is projected t",
                "category": "company",
                "datetime": 1790254680,
                "headline": "Drug Safety Market Forecasts Growth from $7.12B (2026) to $10.21B by 2032, Profiling IQVIA, ICON, Charles River, Oracle & Parexel"
              },
              {
                "id": 142376964,
                "url": "https://finnhub.io/api/news?id=a09892f15cfc2342ebdbd7eccba7685a02e38f57612784a3706a8a6459b171a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., September 24, 2026--Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day",
                "category": "company",
                "datetime": 1790251200,
                "headline": "Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day"
              },
              {
                "id": 142381619,
                "url": "https://finnhub.io/api/news?id=a166526344472844f31fa905ede32e817e5f4c62411d5fd86ba2c3facb599293",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/24/Display-Of-Stock-Market-Quotes.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook; other stocks also gained.",
                "category": "company",
                "datetime": 1790244061,
                "headline": "Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday"
              },
              {
                "id": 142379184,
                "url": "https://finnhub.io/api/news?id=c9c3fd21de2cd9847355174c946ed9a05e8fef2bcfe94440baa4e75ebe390b60",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "2026-09-24. The following slide deck was published by Charles River Laboratories International, Inc.",
                "category": "company",
                "datetime": 1790242663,
                "headline": "Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day - Slideshow"
              },
              {
                "id": 142383030,
                "url": "https://finnhub.io/api/news?id=5a23117f1282e193f88adcb943e6c75db8e2046cdfe9de402d6aeecba581c755",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (NYSE: CRL) will host its 2026 Investor Day today, September 24, 2026, starting at 9:00 a.m. ET.The Company is also introducing the following long-term financial targets",
                "category": "company",
                "datetime": 1790237297,
                "headline": "Charles River Laboratories International Reiterates FY26 Revenue, Non-GAAP Earnings Outlook, Expects FY30 Organic Revenue Growth In Range Of 5% To 7%"
              },
              {
                "id": 142373385,
                "url": "https://finnhub.io/api/news?id=d48861e44962fa08c169889e4ad177ad893cd5c7d830c81b9ae4b7b19d9f66a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Pharma R&D outsourcing is rising as CROs use AI, genomics and advanced screening to cut costs, accelerate discovery, improve compliance and support targeted therapies.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- \"Drug Discovery Services - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Services was estimated at US$10.8 Billion in 2025 and is projected to reach US$26.3 Billion by 2032, growing at a CAGR of 13.6% from 2025 to",
                "category": "company",
                "datetime": 1790236920,
                "headline": "Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave"
              },
              {
                "id": 142356198,
                "url": "https://finnhub.io/api/news?id=25104ceec68d66b64a1f37ae63ab3fec370b55efbfba320a48e272d2b62c2615",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Demand for outsourced pharmacokinetics services is rising, driven by AI, advanced bioanalysis, personalized medicine, biologics and complex global trials.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"Pharmacokinetics Services - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Pharmacokinetics Services was estimated at US$853.5 Million in 2025 and is projected to reach US$1.4 Billion by 2032, growing at a CAGR of 7.8% from 2025 to 2032. Thi",
                "category": "company",
                "datetime": 1790157300,
                "headline": "Capitalize on Pharmacokinetics Outsourcing Disruption as Charles River, Labcorp, WuXi AppTec, Eurofins and Sygnature Compete to Dominate Drug Development ROI"
              },
              {
                "id": 142356193,
                "url": "https://finnhub.io/api/news?id=311de3ed6a22059b7d90ce5ebc5e77b76db8162100a4e5f2ff486a2e18e71b21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.",
                "category": "company",
                "datetime": 1790156462,
                "headline": "3 Unpopular Stocks Walking a Fine Line"
              },
              {
                "id": 142356141,
                "url": "https://finnhub.io/api/news?id=a260791bca67346a94ec770a4d231c653e330840846dbd4be40d1641943f30ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Stricter safety rules, drug innovation and CRO outsourcing drive demand, while imaging, CRISPR and data analytics improve testing and reduce animal use.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"In Vivo Toxicology - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for In Vivo Toxicology was estimated at US$4.5 Billion in 2025 and is projected to reach US$6.0 Billion by 2032, growing at a CAGR of 4.3% from 2025 to 2032. This comprehensive re",
                "category": "company",
                "datetime": 1790151000,
                "headline": "Capitalize on the In Vivo Toxicology Shake-Up: Benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Thermo Fisher Before R&D Shifts Redraw Global Market Share"
              },
              {
                "id": 142356200,
                "url": "https://finnhub.io/api/news?id=4b7121759d1529c866f178de93b9efff8f881af028291fe6bdaa7da2428908cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Pharma companies are expanding drug discovery outsourcing to cut costs, access CRO expertise and AI tools, speed pipelines, manage regulatory complexity, and advance targeted therapies.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"Drug Discovery Outsourcing - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Outsourcing was estimated at US$2.8 Billion in 2025 and is projected to reach US$4.5 Billion by 2032, growing at a CAGR",
                "category": "company",
                "datetime": 1790150880,
                "headline": "Capitalize on the Drug Discovery Outsourcing Shift: Benchmark Charles River, WuXi AppTec, Evotec, Labcorp and Sygnature to Secure R&D ROI and Outsmart the Global Market"
              },
              {
                "id": 142356201,
                "url": "https://finnhub.io/api/news?id=2d2bd2cab7ad130f538257142b21d0e7bc607f853a5295897c62739df0844c07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Stricter safety rules and drug innovation are boosting demand, while high-throughput screening, predictive analytics, biomarkers, and non-animal methods create new opportunities.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"Toxicology Testing Services - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Toxicology Testing Services was estimated at US$41.6 Billion in 2025 and is projected to reach US$59.8 Billion by 2032, growing at a CAGR of",
                "category": "company",
                "datetime": 1790150760,
                "headline": "Capitalize on the Toxicology Testing Services Market Shift: Benchmark Labcorp, Charles River, Eurofins, SGS and WuXi AppTec to Secure Growth and Outpace Disruption"
              },
              {
                "id": 142340388,
                "url": "https://finnhub.io/api/news?id=f2b585db9bcaae9e84130e615a8e8ef41261f486b04f1b7c75b84e8417f50f6d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.",
                "category": "company",
                "datetime": 1790094901,
                "headline": "These S&P500 stocks are moving in today's session"
              },
              {
                "id": 142331584,
                "url": "https://finnhub.io/api/news?id=d33ece3ee562a4822bfaeaa446373e43f534cc74eba85ad447ffa3c152138c7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "AI-driven screening, advanced imaging and demand for targeted therapies are accelerating FBDD, creating opportunities in oncology, neurology and traditionally undruggable targets.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"Fragment-based Drug Discovery - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Fragment-based Drug Discovery was valued at US$977 Million in 2024 and is projected to reach US$1.6 Billion by 2030, growing at a CAGR of",
                "category": "company",
                "datetime": 1790065920,
                "headline": "Disrupt Drug Discovery and Secure R&D ROI: Benchmark Fragment-Based Strategies from Astex, Evotec, Charles River, Schrödinger and Vernalis Through 2030"
              },
              {
                "id": 142331588,
                "url": "https://finnhub.io/api/news?id=ca0199f1023abdccb934011e5eeecbc6e27a4bede2603c32f0daa59bdad6d121",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "PDX adoption is rising as pharma seeks predictive oncology models for precision medicine, biomarker discovery and drug screening, supported by sequencing advances and research partnerships.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"Patient Derived Xenograft / PDX Models - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Patient Derived Xenograft / PDX Models was valued at US$467.5 Million in 2024 and is projected to reach US$1 Billion b",
                "category": "company",
                "datetime": 1790065740,
                "headline": "Capitalize on the Global PDX Models Shift: Benchmark Charles River, Crown Bioscience, Champions Oncology, The Jackson Laboratory and Oncodesign to Secure Precision Oncology ROI"
              },
              {
                "id": 142328488,
                "url": "https://finnhub.io/api/news?id=bc62eb43c32dce5bfd015e09762d0e8c734bea7afb5cfe2391be8b10ca2ca304",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Demand is rising for faster, accurate ADME-Tox testing, driven by complex biologics, tighter regulation, personalized medicine, and adoption of high-throughput, in vitro and in silico methods.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"ADME-Toxicology Testing - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for ADME-Toxicology Testing was valued at US$10 Billion in 2024 and is projected to reach US$18.8 Billion by 2030, growing at a CAGR o",
                "category": "company",
                "datetime": 1790065080,
                "headline": "Capitalize on the ADME-Toxicology Testing Shift: Benchmark Charles River, Thermo Fisher, Eurofins, WuXi AppTec and Evotec to Accelerate R&D ROI and Outpace Disruption"
              },
              {
                "id": 142319439,
                "url": "https://finnhub.io/api/news?id=e74103a9743a075eb466d899fb135f9e669f504b3b882d1ade6c13cb524db239",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "On August 20, Charles River Laboratories (NYSE:CRL) announced a collaboration with Medigen Vaccine Biologics Corp/MVC to apply next-generation sequencing to MVC’s new multivalent enterovirus vaccine program. On its own, the deal is small. But it shows Charles River finding fresh uses for the sequencing technology it picked up through an earlier acquisition, and it lands […]",
                "category": "company",
                "datetime": 1790044484,
                "headline": "Charles River’s (CRL) Vaccine Push Meets A Bumpy Quarter"
              },
              {
                "id": 142319440,
                "url": "https://finnhub.io/api/news?id=8f099109d81ba5b5c58bec5df08cfdf88fa63fe43fe21985b8aecadc1e0c3414",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "On September 8, Charles River Laboratories (NYSE:CRL) said its newly automated cartridge manufacturing suite for Endosafe endotoxin testing had reached full operational capacity in the third quarter, a milestone it had been building toward since the system went fully live in July. The timing matters. Charles River has spent much of 2026 shedding businesses and […]",
                "category": "company",
                "datetime": 1790044183,
                "headline": "Charles River’s (CRL) New Automation Push Meets Old Margin Problems"
              },
              {
                "id": 142311611,
                "url": "https://finnhub.io/api/news?id=8c7135d0fa6090d4f7191c1c0d84f3470436760a453a710fda033133796434cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Riverwater Partners, an investment management company, released its ‘Sustainable Value Strategy’ Q2 2026 investor letter. The letter can be downloaded here. Small-cap stocks achieved their best first-half performance since 1991, with the Russell 2500 Value Index rising 17%, driven by the technology sector. The Sustainable Value Strategy underperformed its benchmark in the second quarter. The shortfall […]",
                "category": "company",
                "datetime": 1789993856,
                "headline": "Here’s Why This Strategy Decided to Exit Charles River Laboratories (CRL)"
              },
              {
                "id": 142261772,
                "url": "https://finnhub.io/api/news?id=b64c3b04fde7f7243075a6dccee16015f624f052eec0250b458682ec9700be9b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (CRL) just rolled out rapid cell banking programs built around Next-Generation Sequencing and its Pathoquest acquisition, aiming to shorten development timelines for advanced therapies and strengthen quality and regulatory control. For context, Charles River Laboratories International has seen strong momentum build over the past few months, with a 90-day share price return of 52.25% and a 1-year total shareholder return of 79.42%. These figures point...",
                "category": "company",
                "datetime": 1789762192,
                "headline": "Can Charles River Laboratories International (CRL) Justify Its Valuation On Its Rapid Cell Banking Launch?"
              },
              {
                "id": 142260391,
                "url": "https://finnhub.io/api/news?id=866520911f2da146c0164c72019750534ce8010a7717e119a519d308397d649d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "PGNY vs. CRL: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1789746004,
                "headline": "PGNY vs. CRL: Which Stock Is the Better Value Option?"
              },
              {
                "id": 142253330,
                "url": "https://finnhub.io/api/news?id=c5e220ff1e139b493d102d703a6de08b854b51660a6bee77891455353b749b62",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (NYSE:CRL) unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools. The platform is designed to shorten biologics and advanced therapy cell bank lead times for biopharma clients while supporting regulatory readiness. Charles River states that the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The new rapid cell banking and release...",
                "category": "company",
                "datetime": 1789722884,
                "headline": "What Is Charles River Laboratories International (CRL) Signaling With Its Faster Cell Banking Platform?"
              },
              {
                "id": 142239173,
                "url": "https://finnhub.io/api/news?id=85ab02bf25c7094bdc35e043c21ba7c05fa3d51009ce1b1ee8b2bb5a93ab73d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "The analyst fair value estimate for Charles River Laboratories International has shifted from US$230.93 to US$282.43, a change of about 22% in the updated work. That move sits against Street commentary that now ranges from targets in the low US$200s to just above US$300. This reflects both renewed optimism around growth execution and ongoing discussion about valuation and timing. As you read on, you will see how this evolving price target story fits into the broader narrative and what signals...",
                "category": "company",
                "datetime": 1789708499,
                "headline": "Charles River Laboratories International (CRL) Stock Fair Value Rises After Analysts Lift Targets"
              },
              {
                "id": 142231863,
                "url": "https://finnhub.io/api/news?id=10a6d0daa7d26614f61882869457c3c9efb7e5443ab45f9a2e51d56127b74b99",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International has introduced rapid cell banking programs that shorten cell bank production timelines by about 40% versus the 20‑week industry standard, integrating rapid microbiological methods and CGMP-compliant Next-Generation Sequencing (NGS) to support faster, higher-quality biologic and advanced therapy development. An interesting aspect of this launch is its alignment with Charles River’s Alternative Methods Advancement Project, which aims to cut reliance on...",
                "category": "company",
                "datetime": 1789683388,
                "headline": "What Charles River Laboratories International (CRL)'s Accelerated, NGS-Enabled Cell Banking Platform Means For Shareholders"
              },
              {
                "id": 142231864,
                "url": "https://finnhub.io/api/news?id=593e739b4d869c95d17cf0909214731af8bef4b6b2867cb69882c3902200cd21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 3.6% in the afternoon session after the company announced the launch of rapid cell banking programs designed to accelerate release timelines.",
                "category": "company",
                "datetime": 1789683017,
                "headline": "Why Charles River Laboratories (CRL) Stock Is Trading Up Today"
              },
              {
                "id": 142224593,
                "url": "https://finnhub.io/api/news?id=6ad8f53023808dd818c5fb4e0dbf3bf7ef3c55ee984a482592b617ca1a740d83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., September 17, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) has introduced rapid cell banking programs designed to significantly accelerate release timelines, enabling biopharmaceutical and advanced therapy developers to reach critical milestones faster and bring innovative treatments to patients sooner. By combining rapid cell bank and release packages with advanced characterization using Next-Generation Sequencing (NGS), Charles River delivers a comprehens",
                "category": "company",
                "datetime": 1789646400,
                "headline": "Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines"
              },
              {
                "id": 142197359,
                "url": "https://finnhub.io/api/news?id=60489fd50614fe61d828e50cb5471c4bf5938520da3eae9ad24994eeeff76955",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "What a fantastic six months it’s been for Charles River Laboratories. Shares of the company have skyrocketed 79.5%, hitting $272.74. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1789571812,
                "headline": "3 Reasons to Sell CRL and 1 Stock to Buy Instead"
              },
              {
                "id": 142164697,
                "url": "https://finnhub.io/api/news?id=f87e70418d4cccf16f505216a16eb0b4c07db5295f76c722453ec95062ef86f0",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (CRL) 2026 Global Healthcare Conference September 15, 2026 9:40 AM EDTCompany ParticipantsGlenn Coleman -...",
                "category": "company",
                "datetime": 1789475497,
                "headline": "Charles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript"
              },
              {
                "id": 142138791,
                "url": "https://finnhub.io/api/news?id=397c4265b81776cbba9ecfaa38fa6602b07b77abb57ab57d1c789e2ca3659317",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (CRL) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDTCompany...",
                "category": "company",
                "datetime": 1789389099,
                "headline": "Charles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              },
              {
                "id": 142137074,
                "url": "https://finnhub.io/api/news?id=ed61199d8e769d6ae13564b8886127c0d035534ea2808856e63e0e001fe7722c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "FIGS, APH and MSFT post strong gains as Zacks upgrades and model portfolios spotlight stocks outperforming the broader market.",
                "category": "company",
                "datetime": 1789387860,
                "headline": "Beat the Market the Zacks Way: FIGS, Microsoft, Amphenol in Focus"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 75,
            "discarded_article_count": 56
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.7,
        "grade": "較差",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 0.4,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.4,
            "vcp_reason": "站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 959420,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 968530,
              "avg_vol_20": 1033290,
              "avg_vol_30": 959420,
              "range_pct_10": 0.1612251655629139,
              "range_pct_20": 0.20668870860927147,
              "range_pct_30": 0.21864238410596018,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.0094953200892205,
              "dist_to_20d_high": 0.09390936375365622,
              "down_shrink_days": 2,
              "breakout_level_20d": 333.29999,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.7373920945024992
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "較差",
        "items": {
          "position": {
            "score": 1.3,
            "details": {
              "atrPct": 3.8246357615894038,
              "turnoverUsdM": 284.281962,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.CRL",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 278.8992,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 2,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 7.6,
            "take_profit_price": 328.3349,
            "target_multiplier": 1.9,
            "technical_strength": 1.8,
            "take_profit_percent": 8.7
          },
          "positionPoints": 1.3,
          "stopLossPoints": 1.2,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 7.6492715231788075,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 11.5504,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.82
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "強勢區",
      "score": 10,
      "value": 86.74
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0632
    },
    "kdj": {
      "d": 42,
      "j": 23.58,
      "k": 35.86,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 66.4
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 1635131,
      "recentSlope": -118146.9,
      "previousSlope": -28860
    },
    "rsi": 56.27,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 329.8166,
      "position": "SAR喺價上",
      "distancePct": 9.21,
      "previousTrend": "下降"
    },
    "ma50": 287.2762,
    "macd": {
      "macd": 5.897876045660439,
      "trend": "強烈看漲",
      "signal": 5.818282418289764,
      "histogram": 0.07959362737067543
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 293.4293,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 15
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.91,
      "score": 4,
      "avgVolume": 1029617,
      "currentVolume": 941331
    },
    "derived": {
      "ma20": 293.487,
      "ma50": 287.2762,
      "prevClose": 299.02,
      "avgVolume10": 983253,
      "avgVolume20": 1029617,
      "changePercent": 1,
      "avgVolumeForScore": 1029617
    },
    "ma_cross": {
      "ma20": 293.487,
      "ma50": 287.2762,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 292.0575,
      "prevMa50": 285.9186,
      "spreadPct": 2.16,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 274.919,
      "upper": 312.055,
      "position": "上半部"
    },
    "rsi_short": 41.11,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.91
    }
  }
}

{
  "close": 302,
  "volume": 941331,
  "changePercent": 1
}